|Mr. Jason Patrick Meyenburg M.B.A., M.D.||CEO, Pres & Director||530.29k||N/A||1977|
|Dr. Georges Gemayel C.F.A., Ph.D.||Exec. Chair||N/A||N/A||1960|
|Mr. Brian Piekos||Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer||N/A||N/A||1975|
|Dr. Walter Strapps Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Precillia Redmond||Chief People Officer||N/A||N/A||N/A|
|Dr. Samuel B. Barone||Chief Medical Officer||N/A||N/A||1973|
|Avner Ingerman M.D.||Chief Devel. Officer||N/A||N/A||N/A|
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Gemini Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.